SOMATULINE AUTOGEL SOLUTION (EXTENDED RELEASE)

País: Canadá

Língua: inglês

Origem: Health Canada

Ingredientes ativos:

LANREOTIDE (LANREOTIDE ACETATE)

Disponível em:

IPSEN BIOPHARMACEUTICALS CANADA INC

Código ATC:

H01CB03

DCI (Denominação Comum Internacional):

LANREOTIDE

Dosagem:

60MG

Forma farmacêutica:

SOLUTION (EXTENDED RELEASE)

Composição:

LANREOTIDE (LANREOTIDE ACETATE) 60MG

Via de administração:

SUBCUTANEOUS

Unidades em pacote:

60MG/SYRINGE

Tipo de prescrição:

Prescription

Área terapêutica:

OTHER MISCELLANEOUS THERAPEUTIC AGENTS

Resumo do produto:

Active ingredient group (AIG) number: 0151653006; AHFS:

Status de autorização:

APPROVED

Data de autorização:

2010-09-13

Características técnicas

_SOMATULINE_
_®_
_ AUTOGEL_
_®_
_ _(lanreotide injection)_ _
_Page 1 of 57_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
SOMATULINE
® AUTOGEL
®
lanreotide injection
Extended release solution
60 mg, 90 mg, 120 mg lanreotide (as lanreotide acetate)/unit
(syringe), subcutaneous
Antigrowth hormone
Ipsen Biopharmaceuticals Canada Inc.
5050 Satellite Drive, Suite 500
Mississauga, Ontario
L4W 0G1
www.ipsen.ca
Date of Initial Authorization:
JUL 17, 2006
Date of Revision:
AUG 08, 2023
Submission Control Number: 268030
_ _
_SOMATULINE_
_®_
_ AUTOGEL_
_®_
_ (lanreotide injection) _
_Page 2 of 57_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Reproductive Health:
Female and Male Potential, Fertility
12/2022
7 WARNINGS AND PRECAUTIONS, Reproductive Health:
Female and Male Potential, Teratogenic Risk
12/2022
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
12/2022
7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic
06/2023
11 STORAGE, STABILITY AND DISPOSAL
08/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT
LISTED
.
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
.............................................................................................................
4
1.2
Geriatrics
.............................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
...................................................... 5
4
DOSAGE AND ADMINISTRATION
..............................................................................
5
4.1
Dosing Considerations
.........................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
..................................................... 6
4.3
Reconsti